These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 18823466)

  • 21. Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
    Sadique MZ; Grieve R; Harrison DA; Cuthbertson BH; Rowan KM
    Crit Care; 2011; 15(5):R228. PubMed ID: 21943177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.
    Hodder RV; Hall R; Russell JA; Fisher HN; Lee B
    Crit Care; 2009; 13(3):R78. PubMed ID: 19457240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drotrecogin alfa (activated): real-life use and outcomes for the UK.
    Rowan KM; Welch CA; North E; Harrison DA
    Crit Care; 2008; 12(2):R58. PubMed ID: 18430215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis.
    Levy M; Levi M; Williams MD; Antonelli M; Wang D; Mignini MA
    Intensive Care Med; 2009 Jul; 35(7):1196-203. PubMed ID: 19367397
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obesity does not alter the pharmacokinetics of drotrecogin alfa (activated) in severe sepsis.
    Levy H; Small D; Heiselman DE; Riker R; Steingrub J; Chen R; Qualy RL; Darstein C; Mongan E
    Ann Pharmacother; 2005 Feb; 39(2):262-7. PubMed ID: 15632220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [PROWESS, ENHANCE and ADDRESS: clinical implications for the treatment with drotrecogin alfa (activated)].
    Cobas Meyer M; Langenfeld H; Rossaint R; Sablotzki A
    Anaesthesist; 2006 Jun; 55 Suppl 1():16-23. PubMed ID: 16680442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis.
    Chawla LS; Seneff MG; Nelson DR; Williams M; Levy H; Kimmel PL; Macias WL
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):22-30. PubMed ID: 17699383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The protein C pathway: implications for the design of the RESPOND study.
    Vangerow B; Shorr AF; Wyncoll D; Janes J; Nelson DR; Reinhart K
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S4. PubMed ID: 18269691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Venous and arterial thromboembolism in severe sepsis.
    Levine RL; LeClerc JR; Bailey JE; Monberg MJ; Sarwat S
    Thromb Haemost; 2008 May; 99(5):892-8. PubMed ID: 18449418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.
    Dhainaut JF; Yan SB; Margolis BD; Lorente JA; Russell JA; Freebairn RC; Spapen HD; Riess H; Basson B; Johnson G; Kinasewitz GT;
    Thromb Haemost; 2003 Oct; 90(4):642-53. PubMed ID: 14515185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis.
    Annane D; Mira JP; Ware LB; Gordon AC; Hinds CJ; Christiani DC; Sevransky J; Barnes K; Buchman TG; Heagerty PJ; Balshaw R; Lesnikova N; de Nobrega K; Wellman HF; Neira M; Mancini ADJ; Walley KR; Russell JA
    Ann Intensive Care; 2018 Jan; 8(1):16. PubMed ID: 29388048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis.
    de Pont AC; Schultz MJ
    Crit Care; 2009; 13(1):113. PubMed ID: 19226446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers of thrombosis, fibrinolysis, and inflammation in patients with severe sepsis due to community-acquired pneumonia with and without Streptococcus pneumoniae.
    Vail GM; Xie YJ; Haney DJ; Barnes CJ
    Infection; 2009 Aug; 37(4):358-64. PubMed ID: 19169631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
    Micek ST; Isakow W; Shannon W; Kollef MH
    Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis.
    De Backer D; Verdant C; Chierego M; Koch M; Gullo A; Vincent JL
    Crit Care Med; 2006 Jul; 34(7):1918-24. PubMed ID: 16715034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
    Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
    Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of refractory septic shock with drotrecogin alpha (activated).
    Vieillard-Baron A; Caille V; Charron C; Belliard G; Aegerter P; Page B; Jardin F
    Intensive Care Med; 2009 Jul; 35(7):1204-9. PubMed ID: 19529911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective evaluation of urine microscopy in septic and non-septic acute kidney injury.
    Bagshaw SM; Haase M; Haase-Fielitz A; Bennett M; Devarajan P; Bellomo R
    Nephrol Dial Transplant; 2012 Feb; 27(2):582-8. PubMed ID: 21669886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated).
    Opal SM; Garber GE; LaRosa SP; Maki DG; Freebairn RC; Kinasewitz GT; Dhainaut JF; Yan SB; Williams MD; Graham DE; Nelson DR; Levy H; Bernard GR
    Clin Infect Dis; 2003 Jul; 37(1):50-8. PubMed ID: 12830408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Septic shock caused by Streptococcus pneumoniae in a post-splenectomy patient successfully treated with recombinant human activated protein C.
    Schumann C; Triantafilou K; Kamenz J; Hanke H; Triantafilou M; Wittemann S; Joos T; Hombach V; Schneider EM; Lepper PM
    Scand J Infect Dis; 2006; 38(2):139-42. PubMed ID: 16449010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.